Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Acute lymphoblastic leukemia (ALL)

CD19

An investigator-led clinical study suggests T cells modified to express a chimeric antigen receptor (CAR) targeting CD19 could help treat patients with relapsed B cell ALL (B-ALL). Prior clinical studies with CD19-targeting CAR T cells have been in less aggressive B cell tumors. In a Phase I trial, five patients with relapsed B-ALL treated with T cells expressing the CD19-specific CAR, termed 19-28z, all went into complete remission. Next steps include expanding the cohort of patients with B-ALL treated with this protocol and conducting preclinical studies to test the potential of the approach for targeting solid tumors.
Novartis AG and the University of Pennsylvania have CTL019, autologous T cells expressing a CAR targeting CD19, in
Phase I/II testing in ALL.

SciBX 6(15); doi:10.1038/scibx.2013.358
Published online April 18, 2013

Patented; undisclosed partner has an exclusive option to the technology

Brentjens, R.J. et al. Sci. Transl. Med.; published online March 20, 2013;
doi:10.1126/scitranslmed.3005930
Contact: Renier J. Brentjens, Memorial Sloan-Kettering Cancer Center,
New York, N.Y.
e-mail:

brentjer@mskcc.org
Contact: Michel Sadelain, same affiliation as above
e-mail:

m-sadelain@ski.mskcc.org